Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies (BHC – Research Report) today. The company’s shares closed yesterday at $8.09.
According to TipRanks, Sulewski is a 4-star analyst with an average return of 19.3% and a 68.57% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals, Bausch Health Companies, and Cormedix.
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $10.80, implying a 33.50% upside from current levels. In a report released yesterday, RBC Capital also assigned a Hold rating to the stock with a $10.00 price target.
Based on Bausch Health Companies’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.41 billion and a GAAP net loss of $39 million. In comparison, last year the company earned a revenue of $2.19 billion and had a GAAP net loss of $410 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Companies (BHC) Company Description:
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
Read More on BHC:
- Bausch Health Reports Growth and Milestones
- Bausch Health price target raised to $9 from $7 at Piper Sandler
- Bausch Health price target lowered to $11 from $12 at RBC Capital
- Bausch Health put volume heavy and directionally bearish
- Jefferies healthcare analyst holds an analyst/industry conference call
